Actinium Pharmaceuticals, a biopharmaceutical company developing targeted payload immunotherapeutics for the treatment of advanced cancers, has entered into an agreement with Zevacor Pharma for the clinical production and supply of Iomab-B for the upcoming Phase 3 SIERRA trial. Zevacor will perform the GMP manufacturing, testing, releasing and distribution of Iomab-B for the trial. Iomab-B is a radioimmunotherapy intended to be an induction and conditioning agent prior to a bone marrow transplan...